PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2023
CASE
AUTH/3777/6/23 AstraZeneca

AstraZeneca Trixeo eligibility checklist: narrow-angle glaucoma counselling text omitted (no breach on appeal) | AUTH/3777/6/23

Complaint said a Trixeo HCP eligibility checklist omitted SmPC counselling/stop-treatment text for acute narrow-angle glaucoma. Panel found breaches, but Appeal Board overturned:…

2021
CASE
GlaxoSmithKline

GSK breached ABPI Code over Zejula AE management webpage that omitted discontinuation scenarios

PMCPA ruled GSK’s Zejula β€œPRIMA AE management” webpage misleading for implying AEs could be managed by dose interruption/modification without highlighting when SmPC…

2023
CASE
AUTH/3790/7/23 Moderna ⭐ Case of the Week

AUTH/3790/7/23: Ex-employee v Moderna (preprint data in presentations) β€” No breach

Anonymous ex-employee alleged Moderna misused preprint vaccine effectiveness data, cherry-picked graphs and sought UK contract advantage via JCVI presentations. Panel found no…

2023
CASE
AUTH/3854/11/23 GlaxoSmithKline

GSK: LinkedIn β€˜celebrate’ of third‑party niraparib trial post ruled off‑label promotion to the public (AUTH/3854/11/23)

A UK-based GSK Global employee β€˜celebrated’ a third-party LinkedIn post about promising niraparib results in glioblastoma. PMCPA found promotion to the public…

2021
CASE
Celltrion Healthcare UK

Celltrion: representative’s unsubstantiated β€œcost neutral” NICE/TAG justification and failure to provide substantiation for Remsima SC

A pharmacist complained about a rep’s claim that NICE said infliximab SC fell under infliximab IV TAG due to cost neutrality. Panel…

2024
CASE
AUTH/3901/5/24 GlaxoSmithKline

AUTH/3901/5/24: Complainant v GSK β€” Jemperli HCP website (mobile vs desktop certification and β€œmanageable safety profile” claim) β€” No breach

Complaint alleged Jemperli HCP webpages weren’t properly certified for mobile due to layout/navigation differences and that a β€œmanageable safety profile” claim was…

2024
CASE
AUTH/3922/6/24 GlaxoSmithKline

AUTH/3922/6/24: Complainant v GSK β€” Trelegy banner alleged off-label switch claim (No breach)

Complaint alleged a Trelegy Ellipta rotating banner promoted an unlicensed switch from three inhalers (incl. SABA). PMCPA Panel found no breach of…

2008
CASE
Pfizer

Pfizer letter requesting addition of Ecalta and Celsentri to hospital e-prescribing system ruled promotional without prescribing information

A hospital pharmacist complained about a Pfizer-authorised letter asking hospitals to add Ecalta and Celsentri to electronic prescribing/dispensing systems. The Panel ruled…

2008
CASE
Trinity-Chiesi Pharmaceuticals

Trinity-Chiesi letter promoting Clenil: omission of 200mcg cost comparison not misleading in Scottish context

A PCT pharmacist alleged a Clenil cost-comparison chart was misleading because it omitted 200mcg data. The Panel found the Scottish Drug Tariff…

2008
CASE
AUTH/2156/8/08 Sanofi

AUTH/2156/8/08: GlaxoSmithKline v Sanofi Pasteur MSD – Gardasil letter to health professionals

A letter about the UK HPV vaccine tender was ruled promotional for Gardasil, lacked prescribing information and adverse event reporting guidance, and…

2008
CASE
AUTH/2141/7/08 Sanofi ⭐ Case of the Week

AUTH/2141/7/08: Novo Nordisk v Sanofi-Aventis – Promotion of Lantus (24-hour efficacy and hypoglycaemia claims)

Complaint about Lantus promotional leavepieces and a mailer. Issues included β€œ24-hour efficacy” wording and comparative hypoglycaemia claims based on pooled observational data.…

2008
CASE
Pfizer

Pfizer Toviaz journal advertisement: prescribing information missing for promoted tolterodine (Detrusitol)

A GP complained that a Toviaz ad also promoted tolterodine without prescribing information. The Panel ruled a breach for missing obligatory information,…

2008
CASE
Boehringer Ingelheim

Anonymous doctor v Lilly and Boehringer Ingelheim: sponsored journal supplement found to be disguised promotion

A journal-lookalike supplement reporting a company-run symposium was presented as a sponsored independent forum report. The Panel ruled it was disguised promotion,…

2009
CASE
AUTH/2203/1/09 Pfizer

Pfizer Champix ad: superiority claim vs NRT ruled misleading due to lack of study context (AUTH/2203/1/09)

A Champix journal ad claimed significantly greater quit success vs NiQuitin patch. PMCPA ruled the claim misleading because the ad didn’t explain…

2019
CASE
AUTH/3180/4/19 AstraZeneca

AstraZeneca sales manager’s personal Instagram post about KOL nurse ruled in scope and unethical; conflict of interest not declared (AUTH/3180/4/19)

A respiratory nurse complained about a sales manager’s personal Facebook/Instagram posts referencing a nurse KOL. Panel found one Instagram post in scope…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training